课题基金 / 基金详情

GENOMIC INSTABILITY & CLONALITY IN TUMOR PROGRESSION

GENOMIC INSTABILITY & CLONALITY IN TUMOR PROGRESSION
基因组不稳定
批准号:
3482453
负责人:
PHILIP FROST
金额:
$19.22万
依托单位国家:
美国
项目类别:
财政年份:
1984
资助国家:
美国
项目状态:
已结题
起止时间:
1984-08-01 至 1992-02-29

项目摘要

项目成果

PHILIP FROST的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This proposal can be divided into three sections. The first, is direct extension of our previous work on genomic instability in tumor progression. We had measured the rate of spontaneous mutation and of the generation of karyotypic changes in metastatic and non-metastatic cells but could not demonstrate a difference in either parameter between the cell types. However, because the parameters we chose may have been to finite (point mutations) or to broad (cytogenetic changes), we have chosen to look at homologous rearrangements (HR) as a means of determining if significant differences in HR for metastatic and non-metastatic cells can be detected. The second section of this proposal extends our interest in progression to the issue of clonal dominance in relationship to the development of progressed, i.e. metastatic cells. Recent reports have indicated (in a murine model) that as tumors become metastatic a single clone dominates not only the primary tumor, but also the metastases. We will use molecular techniques to address this issue in human tumors and determine whether clonal dominance is a feature of human neoplasia. Since we believe the mechanism by which clonal dominance occurs relates to genomic instability (please see text), these analyses establish a reasonable link between genomic instability and progression. This issue will also be analyzed in a carcinogenesis model during the conversion of papillomas to carcinomas. The third section of this proposal deals with our hypothesis that tumor progression is of two types, namely the classic form as seen in colon carcinoma (Type 1) and the accelerated form, (Type 2), which occurs in most other tumors. We have chosen unknown primary tumors as being the quintessential example of a Type 2 tumor progressor. These studies are aimed at defining Type 2 tumors using karyotypic analyses in an effort to define unique chromosomal changes in these tumors. We also plan to use the approaches contained in the first two sections to study the relationship between Type 1 and Type 2 progressors. We are, therefore, proposing a continuation of our earlier work and Its extension to newer areas using molecular genetic techniques to assess genomic instability and tumor progression.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
5-azacytidine induction of thymidine kinase in a spontaneously enzyme-deficient murine tumor line.
5-氮杂胞苷在自发酶缺陷的小鼠肿瘤系中诱导胸苷激酶。
DOI: 10.1016/0014-4827(84)90596-2
发表时间: 1984
期刊: Experimental cell research
影响因子: 3.7
作者: [Liteplo,RG, Frost,P, Kerbel,RS]
通讯作者: Kerbel,RS
Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.
转移中的肿瘤进展:使用凝集素抗性肿瘤变体的实验方法。
DOI: 10.1007/bf00048223
发表时间: 1982
期刊: Cancer metastasis reviews
影响因子: --
作者: [Kerbel,RS, Dennis,JW, Largarde,AE, Frost,P]
通讯作者: Frost,P
Characterization of in vitro immunoselected variants from a highly metastatic murine tumor for alterations in malignant behavior in vivo.
来自高度转移性小鼠肿瘤的体外免疫选择变体的表征,用于改变体内恶性行为。
DOI: 10.1002/ijc.2910330518
发表时间: 1984
期刊: International journal of cancer
影响因子: 6.4
作者: [Liteplo,RG, Frost,P, Donaghue,TP, Kerbel,RS]
通讯作者: Kerbel,RS
Is the immunotherapy of metastasis feasible?
转移的免疫治疗可行吗?
DOI: --
发表时间: 1986
期刊: Symposium on Fundamental Cancer Research
影响因子: --
作者: [Frost,P, Kerbel,RS]
通讯作者: Kerbel,RS
10
    MUTAGE/UV INDUCED IMMUNE VARIANTS IN METASTASIS THERAPY
    ALIEN GENE TRANSFECTION IN THE THERAPY OF METASTASES
    MUTAGE/UV INDUCED IMMUNE VARIANTS IN METASTASIS THERAPY
    MUTAGE/UV INDUCED IMMUNE VARIANTS IN METASTASIS THERAPY
    国内基金
    海外基金
    CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究